EDSA - Edesa gets Health Canada nod to start mid-stage study for vitiligo drug

• Edesa Biotech ( NASDAQ: EDSA ) said it received approval from Health Canada for a phase 2 trial of EB06 monoclonal antibody to treat vitiligo.
• Vitiligo is an autoimmune disease that causes skin to lose color in patches.
• Patients will receive intravenous infusions of either EB06 or placebo during the treatment period, followed by a follow-up period. The trial will enroll about 120 adults with moderate to severe generalized vitiligo.
• Edesa said its drug targets autoreactive T cells that destroy the pigment-producing cells of the epidermis. Specifically, EB06 binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors. CXCL10 is highly expressed in patients with vitiligo, the company added.
• EDSA +1.99% to 1.54 premarket Feb. 1

For further details see: